Prelude Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Prelude Capital Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-500	Closed	-$3K	–	2298
2020 Q3	$3K	Buy	+500	New	+$2.47K	﹤0.01%	1654

Prelude Capital Management's AVEO Position: Q1 2023 in Review

Prelude Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 504,972 shares — an estimated $7.55M sold.

Prelude Capital Management first reported a position in AVEO in Q1 2014 and held it in 11 quarters. The position peaked at $7.55M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

Prelude Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Prelude Capital Management sold 504,972 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $7.55M.
Prelude Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2014 and held it in 11 quarters.
Prelude Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $7.55M in Q4 2022.
0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Prelude Capital Management's 13F filing for Q1 2023, filed 15 May 2023.